Table 2.
Clinical features of the patients with mutations in IDH1/IDH2 and TP53 genes.
| Clinical characteristics | N (n = 106) | IDH1/IDH2 mutated (n = 14) | TP53 mutated (n = 37) |
|---|---|---|---|
| Gender | |||
| Male | 53 | 8 (15.1%) | 20 (37.7%) |
| Female | 53 | 6 (11.3%) | 17 (32.1%) |
| Age | |||
| <56 years old | 51 | 12 (23.5%) | 22 (43.1%) |
| ≥56 years old | 55 | 2 (0.36%) | 15 (27.3%) |
| Karnofsky Scalea | |||
| KPS ≤70 | 56 | 3 (0.5%) | 15 (26.8%) |
| KPS >70 | 45 | 10 (22.2%) | 21 (46.6%) |
| Resectiona | |||
| Subtotal or partial | 54 | 10 (18.5%) | 21 (38.8%) |
| Total | 50 | 4 (0.8%) | 16 (32%) |
| Glioblastoma type | |||
| Primary | 93 | 10 (10.7%) | 29 (31.2%) |
| Secondary | 13 | 4 (30.7%) | 8 (61.5%) |
| Overall survivala (months) | |||
| Median | 7.7 | 30.9 | 9.1 |
aMissing data for several patients.
N: number of patients.